Back to Publications​
Article

Proteomics Consortium Profiling 50K-Plus Samples From Patients With Neurodegenerative Disease

Back to Publications​
Topic/Product:
Alzheimer's, Neurology

Abstract

NEW YORK – The Global Neurodegeneration Proteomics Consortium (GNPC) is putting together the largest set of proteomics data in neurodegenerative disease collected to date with plans to characterize roughly 50,000 plasma samples from individuals with neurodegenerative conditions.

The organization, which operates as a public-private partnership between Johnson & Johnson’s Janssen Research & Development and Gates Ventures, plans in July to release data from the first stage of the project to the broader scientific community.

That data will consist of measurements on roughly 35,000 plasma samples from roughly 25,000 individuals made using technologies including Standard BioTools’ SomaScan, Olink’s Explore HT, Alamar Biosciences’ NULISA platforms, and mass spectrometry, said Niranjan Bose, a managing director at Gates Ventures.

Gates Ventures is also working with Alamar and the Alzheimer’s Disease Data Initiative (where Bose is a member of the advisory board) to collect data on more than 40,000 plasma samples from individuals with neurodegenerative disease. Roughly 10,000 to 15,000 of those samples have or will also be run on the SomaScan 11K and Olink Explore HT platforms and will be released as part of a second GNPC dataset, Bose said. The remainder of the samples will, at least initially, be run only on the Alamar platform.

Read the Full Article
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.